CRISPR Therapeutics (CRSP) Down 5.3% Since Last Earnings Report: Can It Rebound?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·5d ago
More News
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks·7d ago
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
Zacks·10d ago
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
Zacks·11d ago
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
Zacks·18d ago
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks·20d ago
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
Zacks·27d ago
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks·1mo ago
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.
Zacks·1mo ago
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.